Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 8/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.57 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535200 | 0.88 | HPGDS (0.61) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL4370942 | 0.88 | HPGDS (1.00) | HPGDSCYP11B1CYP11B2 | |
| SCHEMBL30504588 | 0.88 | HPGDS (1.00) | HPGDSCYP11B1CYP11B2 | |
| SCHEMBL4407431 | 0.86 | ALDH1A1 (0.68) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL61795 | 0.86 | ALDH1A1 (0.64) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL4145819 | 0.85 | ALDH1A1 (0.59) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL20799517 | 0.85 | ALDH1A1 (0.62) | HPGDSALDH1A1F2GLAHPGD | |
| Hydrochloric Acid SCHEMBL6085328 | 0.85 | ALDH1A1 (0.62) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL1353255 | 0.82 | HPGDS (0.63) | HPGDSALDH1A1F2GLAHPGD | |
| SCHEMBL5405254 | 0.82 | HPGDS (0.55) | HPGDSKDM4EALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | claimed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-1687276-B1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2009-10-14 | — | — | EP | disclosed |
| CN-100537540-C | Process for preparing 3-fluoroquinolines | AVENTIS PHARMA SA (FR) | 2009-09-09 | — | — | CN | disclosed |
| US-7396934-B2 | Process for preparing 3-fluoroquinolines | NOVEXEL (FR) | 2008-07-08 | — | — | US | disclosed |
| CN-1894216-A | Novel process for preparing 3-fluoroquinolines | AVENTIS PHARMA SA (FR) | 2007-01-10 | — | — | CN | disclosed |
| EP-1687276-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2006-08-09 | — | — | EP | disclosed |
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | AVENTIS PHARMA S.A. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005049575-A1 | NOVEL METHOD OF PREPARING 3-FLUORINATED QUINOLINES | NOVEXEL (FR) | 2005-06-02 | — | — | WO | disclosed |
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | HPGDS 480/4885ALDH1A1 2731/4885F2 3837/4885 |
| US-20230061429-A1 | BICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | HPGDS 480/4885ALDH1A1 2731/4885F2 3837/4885 |
| US-20050182259-A1 | Subjecting a substituted quinoline-3-carboxamide compound to Hofmann degradation to obtain amine derivative, forming diazonium salt by reacting amine derivative with borontrifluoride-ethyl ether complex, heating to form 3-fluoroquinolines; intermediate for forming antibacterial compound | QRFPR, NQO2, DHX35 | HPGDS 4341/4885ALDH1A1 2137/4885F2 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.